COMP <GO>
ZTS vs LLY // 10Y YIELD & FRED MACRO BETA
Zoetis Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ZTS 4
— LLY 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ZTS
LAST: $79.72 (+1.17%) • MKT CAP: $32.56B
macro-sensitivity
0.99
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZTS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZTS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.80% | 83.64% | -11.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.70% | 32.36% | -6.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.3x | 36.4x | -26.12 | ZTS | /valuation <GO> |
| Free Cash Flow Yield | 7.01% | 2.30% | +4.71 | ZTS | /fcf-yield <GO> |
| Operating Margin | 34.40% | 40.21% | -5.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | 28.20% | 31.90% | -3.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 2.30% | 45.51% | -43.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.53 | 9.29 | -4.76 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 77.9 | -17.44 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.99 | 0.51 | +0.48 | ZTS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 26.3x | -14.95 | ZTS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $32.56B | $1.33T | -$1.30T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZTS REV | LLY REV | ZTS GROSS % | LLY GROSS % | ZTS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.47B | $65.18B | 71.8% | 83.0% | $2.28B | $16.81B |
| FY 2024 | $9.26B | $45.04B | 70.6% | 81.3% | $2.30B | $8.82B |
| FY 2023 | $8.54B | $34.12B | 44.0% | 79.3% | $1.97B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZTS // BETA 0.99
LLY // BETA 0.51